US 11,938,099 B2
Use of tapinarof for the treatment of atopic dermatitis
John E. Kraus, Pittsboro, NC (US); and James Lee, Durham, NC (US)
Assigned to DERMAVANT SCIENCES GMBH, Basel (CH)
Filed by Dermavant Sciences GmbH, Basel (CH)
Filed on Sep. 1, 2023, as Appl. No. 18/459,778.
Application 18/459,778 is a continuation of application No. 18/163,631, filed on Feb. 2, 2023.
Application 18/163,631 is a continuation of application No. 17/871,663, filed on Jul. 22, 2022, granted, now 11,590,088, issued on Feb. 28, 2023.
Application 16/682,485 is a continuation in part of application No. 16/682,476, filed on Nov. 13, 2019, abandoned.
Application 17/871,663 is a continuation of application No. 16/682,485, filed on Nov. 13, 2019, granted, now 11,497,718, issued on Nov. 15, 2022.
Claims priority of provisional application 62/833,269, filed on Apr. 12, 2019.
Claims priority of provisional application 62/833,276, filed on Apr. 12, 2019.
Claims priority of provisional application 62/760,692, filed on Nov. 13, 2018.
Claims priority of provisional application 62/760,704, filed on Nov. 13, 2018.
Prior Publication US 2023/0414534 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61P 17/04 (2006.01); A61P 17/06 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/0014 (2013.01); A61K 9/107 (2013.01); A61P 17/04 (2018.01); A61P 17/06 (2018.01)] 15 Claims
 
1. A method for treating mild to severe atopic dermatitis in a subject comprising topically administering a topical composition containing about 1.0% tapinarof to affected areas of the subject once a day, wherein after topically administering the topical composition an Investigator Global Assessment (IGA) score is improved by 2 grades.